54
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Dynamic changes in circulating T follicular helper cell composition predict neutralising antibody responses after yellow fever vaccination

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objectives

          T follicular helper (Tfh) cells are the principal T helper cell subset that provides help to B cells for potent antibody responses against various pathogens. In this study, we took advantage of the live‐attenuated yellow fever virus (YFV) vaccine strain, YF‐17D, as a model system for studying human antiviral immune responses in vivo following exposure to an acute primary virus challenge under safe and highly controlled conditions, to comprehensively analyse the dynamics of circulating Tfh (cTfh) cells.

          Methods

          We tracked and analysed the response of cTfh and other T and B cell subsets in peripheral blood of healthy volunteers by flow cytometry over the course of 4 weeks after YF‐17D vaccination.

          Results

          Using surface staining of cell activation markers to track YFV‐specific T cells, we found increasing cTfh cell frequencies starting at day 3 and peaking around 2 weeks after YF‐17D vaccination. This kinetic was confirmed in a subgroup of donors using MHC multimer staining for four known MHC class II epitopes of YF‐17D. The subset composition of cTfh cells changed dynamically during the course of the immune response and was dominated by the cTfh1‐polarised subpopulation. Importantly, frequencies of cTfh1 cells correlated with the strength of the neutralising antibody response, whereas frequencies of cTfh17 cells were inversely correlated.

          Conclusion

          In summary, we describe detailed cTfh kinetics during YF‐17D vaccination. Our results suggest that cTfh expansion and polarisation can serve as a prognostic marker for vaccine success. These insights may be leveraged in the future to improve current vaccine design and strategies.

          Abstract

          We tracked circulating T follicular helper (cTfh) cells in the blood of healthy individuals who received the yellow fever (YF) vaccine YF‐17D. We found that cTfh1‐polarised cells dominated the cTfh response and that their frequency on day 14 predicted YF virus‐neutralising antibody levels detected on day 28 after vaccination, thus highlighting the prognostic value of cTfh cells for monitoring of vaccine outcomes.

          Related collections

          Most cited references26

          • Record: found
          • Abstract: found
          • Article: not found

          Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines.

          To explore the human T cell response to acute viral infection, we performed a longitudinal analysis of CD8(+) T cells responding to the live yellow fever virus and smallpox vaccines--two highly successful human vaccines. Our results show that both vaccines generated a brisk primary effector CD8(+) T cell response of substantial magnitude that could be readily quantitated with a simple set of four phenotypic markers. Secondly, the vaccine-induced T cell response was highly specific with minimal bystander effects. Thirdly, virus-specific CD8(+) T cells passed through an obligate effector phase, contracted more than 90% and gradually differentiated into long-lived memory cells. Finally, these memory cells were highly functional and underwent a memory differentiation program distinct from that described for human CD8(+) T cells specific for persistent viruses. These results provide a benchmark for CD8(+) T cell responses induced by two of the most effective vaccines ever developed.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Follicular helper T cells in immunity and systemic autoimmunity.

            Follicular helper T (T(FH)) cells are essential for B-cell maturation and immunoglobulin production after immunization with thymus-dependent antigens. Nevertheless, the development and function of T(FH) cells have been less clearly defined than classic CD4(+) effector T-cell subsets, including T-helper-1 (T(H)1), T(H)2 and T(H)17 cells. As such, our understanding of the genesis of T(FH) cells in humans and their role in the development of autoimmunity remains incomplete. However, evidence from animal models of systemic lupus erythematosus (SLE) and patients with systemic autoimmune diseases suggests that these cells are necessary for pathogenic autoantibody production, in a manner analogous to their role in promotion of B-cell maturation during normal immune responses. In this Review, I discuss the findings that have increased our knowledge of T(FH)-cell development and function in normal and aberrant immune responses. Such information might improve our understanding of autoimmune diseases, such as SLE, and highlights the potential of T(FH) cells as therapeutic targets in these diseases.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Circulating T FH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity

              Immunization with the inactivated influenza vaccine (IIV) remains the most effective strategy to combat seasonal influenza infections. IIV activates B cells and T follicular helper (TFH) cells and thus engenders antibody-secreting cells and serum antibody titers. However, the cellular events preceding generation of protective immunity in humans are inadequately understood. We undertook an in-depth analysis of B cell and T cell immune responses to IIV in 35 healthy adults. Using recombinant hemagglutinin (rHA) probes to dissect the quantity, phenotype, and isotype of influenza-specific B cells against A/California09-H1N1, A/Switzerland-H3N2, and B/Phuket, we showed that vaccination induced a three-pronged B cell response comprising a transient CXCR5–CXCR3+ antibody-secreting B cell population, CD21hiCD27+ memory B cells, and CD21loCD27+ B cells. Activation of circulating TFH cells correlated with the development of both CD21lo and CD21hi memory B cells. However, preexisting antibodies could limit increases in serum antibody titers. IIV had no marked effect on CD8+, mucosal-associated invariant T, T, and natural killer cell activation. In addition, vaccine-induced B cells were not maintained in peripheral blood at 1 year after vaccination. We provide a dissection of rHA-specific B cells across seven human tissue compartments, showing that influenza-specific memory (CD21hiCD27+) B cells primarily reside within secondary lymphoid tissues and the lungs. Our study suggests that a rational design of universal vaccines needs to consider circulating TFH cells, preexisting serological memory, and tissue compartmentalization for effective B cell immunity, as well as to improve targeting cellular T cell immunity.
                Bookmark

                Author and article information

                Contributors
                simon.rothenfusser@med.uni-muenchen.de
                dirk.baumjohann@uni-bonn.de
                Journal
                Clin Transl Immunology
                Clin Transl Immunology
                10.1002/(ISSN)2050-0068
                CTI2
                Clinical & Translational Immunology
                John Wiley and Sons Inc. (Hoboken )
                2050-0068
                13 May 2020
                May 2020
                : 9
                : 5 ( doiID: 10.1002/cti2.v9.5 )
                : e1129
                Affiliations
                [ 1 ] Institute for Immunology Biomedical Center Faculty of Medicine LMU Munich Planegg‐Martinsried Germany
                [ 2 ] Division of Clinical Pharmacology University Hospital LMU Munich Munich Germany
                [ 3 ] Einheit für Klinische Pharmakologie (EKLiP) Helmholtz Zentrum München German Research Center for Environmental Health (HMGU) Neuherberg Germany
                [ 4 ] Laboratory of Immunogenetics and Molecular Diagnostics Department of Transfusion Medicine, Cell Therapeutic Agents and Hemostaseology LMU Munich Munich Germany
                [ 5 ] Division of Infectious Diseases and Tropical Medicine University Hospital LMU Munich Munich Germany
                [ 6 ] German Center for Infection Research, partner site Munich Munich Germany
                [ 7 ] Structural Virology Unit and CNRS UMR 3569 Virology Department Institut Pasteur Paris France
                [ 8 ] Medical Clinic III for Oncology, Hematology, Immuno‐Oncology and Rheumatology University Hospital Bonn University of Bonn Bonn Germany
                [ 9 ]Present address: Department of Pharmacy LMU Munich Munich Germany
                Author notes
                [*] [* ] Correspondence

                D Baumjohann, Medical Clinic III for Oncology, Hematology, Immuno‐Oncology and Rheumatology, University Hospital Bonn, University of Bonn, Venusberg‐Campus 1, 53127 Bonn, Germany.

                E‐mail: dirk.baumjohann@ 123456uni-bonn.de

                S Rothenfußer, Division of Clinical Pharmacology, University Hospital, LMU Munich, 80337 Munich, Germany.

                E‐mail: simon.rothenfusser@ 123456med.uni-muenchen.de

                [†]

                Joint first authors.

                [‡]

                Joint senior authors.

                Author information
                https://orcid.org/0000-0002-7667-4285
                https://orcid.org/0000-0002-4879-4159
                https://orcid.org/0000-0003-3589-7535
                https://orcid.org/0000-0002-3590-1525
                https://orcid.org/0000-0002-5153-3371
                https://orcid.org/0000-0003-2264-4395
                https://orcid.org/0000-0001-7383-8750
                https://orcid.org/0000-0001-5111-6845
                https://orcid.org/0000-0003-2069-9501
                https://orcid.org/0000-0002-9556-7207
                https://orcid.org/0000-0003-1151-7614
                https://orcid.org/0000-0001-8385-8288
                Article
                CTI21129
                10.1002/cti2.1129
                7221214
                32419947
                fb730cd7-0a39-4b68-ba1a-db8ce50218f0
                © 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 20 December 2019
                : 06 March 2020
                : 30 March 2020
                Page count
                Figures: 7, Tables: 0, Pages: 16, Words: 8600
                Funding
                Funded by: Medical Faculty of the LMU Munich
                Funded by: Einheit für Klinische Pharmakologie (EKLIP)
                Funded by: Helmholtz Zentrum München
                Funded by: Deutsche Forschungsgemeinschaft , open-funder-registry 10.13039/501100001659;
                Award ID: BA 5132/1‐1
                Award ID: BA 5132/1‐2 (252623821)
                Award ID: B12 (210592381)
                Award ID: 391217598
                Award ID: 404450088
                Funded by: Agence National de Recherche
                Categories
                Original Article
                Original Articles
                Custom metadata
                2.0
                May 2020
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.1 mode:remove_FC converted:14.05.2020

                neutralising antibodies,t follicular helper (tfh) cells,vaccination,viral infection,yellow fever,yf‐17d

                Comments

                Comment on this article